The 80th Annual Meeting of the Japanese Society of Hematology

Sessions

Morning Seminar

26 results  (21 - 26)

  • Morning Seminar

MS3-10

Precision Hematology/Oncology: incorporating next-generation sequencing technologies into clinical practice

Sun. Oct 14, 2018 7:30 AM - 8:15 AM No.10 (Osaka International Convention Center, 10F 1009)

Chair: Seishi Ogawa (Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Japan)

Sponsor: Medical Affairs, Astellas Pharma Inc.

  • Morning Seminar

MS3-11

Recent Topics in T-cell Lymphoma Treatment

Sun. Oct 14, 2018 7:30 AM - 8:15 AM No.11 (Osaka International Convention Center, 10F 1004-5)

Chair: Kenji Ishitsuka (Department of Hematology and Immunology, Kagoshima University Hospital)

Sponsor: Celgene K.K.

  • Morning Seminar

MS3-12

The role of Immune checkpoint inhibitor in hematological malignancies

Sun. Oct 14, 2018 7:30 AM - 8:15 AM No.12 (Osaka International Convention Center, 10F 1006-7)

Chair: Akihiro Tomita (Division of Hematology, Fujita Health University School of Medicine)

Sponsors: MSD K.K./TAIHO PHARMACEUTICAL CO., LTD.

  • Morning Seminar

MS3-13

Gaucher disease and Hematological diseases

Sun. Oct 14, 2018 7:30 AM - 8:15 AM No.13 (Osaka International Convention Center, 11F 1101-2)

Chair: Hirohito Yamazaki (Division of Transfusion Medicine, Kanazawa University Hospital)

Sponsor: Sanofi K.K.

  • Morning Seminar

MS3-14

Contribution of azacitidine to lower-risk MDS

Sun. Oct 14, 2018 7:30 AM - 8:15 AM No.14 (Osaka International Convention Center, 8F 801-2)

Chair: Takahiro Suzuki (Department of Hematology, Kitasato University School of Medicine)

Sponsor: Nippon Shinyaku Co., Ltd.

  • Morning Seminar

MS3-15

EZH2 in the pathogenesis and targeted therapy of B-cell lymphoma

Sun. Oct 14, 2018 7:30 AM - 8:15 AM No.15 (Osaka International Convention Center, 7F 701-2)

Chair: Toshio Kitamura (Division of Cellular Therapy/Division of Stem Cell Signaling The Institute of Medical Science, The University of Tokyo)

Sponsor: Medical HQs, Eisai Co., Ltd.